Eam Investors, LLC Akero Therapeutics, Inc. Transaction History

Eam Investors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$36.89 - $56.88 $227,574 - $350,892	6,169 Added 13.8%	50,856 $2.37 Million
Q1 2023 Jul 12, 2023	BUY	$37.27 - $50.24 $774,470 - $1.04 Million	20,780 Added 86.92%	44,687 $1.71 Million
Q1 2023 May 12, 2023	SELL	$37.27 - $50.24 $1.1 Million - $1.49 Million	-29,605 Reduced 55.32%	23,907 $914,000
Q4 2022 Feb 14, 2023	SELL	$33.44 - $54.8 $1.04 Million - $1.7 Million	-31,095 Reduced 36.75%	53,512 $2.93 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $858,761 - $2.88 Million	84,607 New	84,607 $2.88 Million
Q4 2020 Feb 11, 2021	SELL	$25.12 - $29.89 $1.61 Million - $1.91 Million	-63,928 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$30.79 - $39.92 $1.97 Million - $2.55 Million	63,928 New	63,928 $1.97 Million

193

74.6M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.52B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.